文献速递新药、器械与细胞基因治疗研发临床试验与 GCP

Atidarsagene Autotemcel治疗异染性脑白质营养不良的长期效果

Long-Term Effects of Atidarsagene Autotemcel for Metachromatic Leukodystrophy.
PubMed 文献 · N Engl J Med · 2025-01-01

在两项前瞻性开放标签临床研究与扩大可及项目中,39例接受atidarsagene autotemcel(arsa-cel)治疗的异染性脑白质营养不良(MLD)患者与49例未治疗的自然病史队列比较,中位随访6.76年。症状前晚婴型、症状前早幼型及早期症状早幼型MLD患者接受arsa-cel后严重运动障碍或死亡风险显著低于未治疗者。

要点

  • 症状前晚婴型MLD患者6岁时无严重运动障碍生存率:治疗组100% vs 未治疗组0%。
  • 症状前早幼型MLD患者10岁时无严重运动障碍生存率:治疗组87.5% vs 未治疗组11.2%。
  • 最常见≥3级不良事件为发热性中性粒细胞减少;未发现插入性致癌证据。

核心结论

  • 在症状前晚婴型或早幼型MLD及早期症状早幼型MLD患者中,接受arsa-cel治疗者严重运动障碍或死亡风险显著低于未接受治疗的自然病史队列。

研究设计与样本

  • 两项前瞻性开放标签临床研究及扩大可及项目,共纳入39例接受arsa-cel治疗的MLD患者,与49例未治疗的自然病史队列比较。
  • 主要终点为无严重运动障碍生存(从出生至首次丧失行走及无支撑坐立或任何原因死亡的时间)。
  • 中位随访6.76年(范围0.64至12.19年)。

主要发现

  • 症状前晚婴型MLD患者接受arsa-cel后严重运动障碍或死亡风险显著低于未治疗者(P<0.001)。
  • 症状前早幼型MLD患者接受arsa-cel后严重运动障碍或死亡风险显著低于未治疗者(P=0.04)。
  • 早期症状早幼型MLD患者接受arsa-cel后严重运动障碍或死亡风险显著低于未治疗者(P<0.001)。
  • 6岁时无严重运动障碍生存率:未治疗晚婴型MLD患者0%(95%CI不可评估),治疗的症状前晚婴型MLD患者100%(95%CI 100至100)。
  • 10岁时无严重运动障碍生存率:未治疗早幼型MLD患者11.2%(95%CI 0.9至36.4),治疗的症状前早幼型MLD患者87.5%(95%CI 38.7至98.1),治疗的早期症状早幼型MLD患者80.0%(95%CI 40.9至94.6)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metachromatic leukodystrophy (MLD) is an ultrarare, severe lysosomal storage disorder caused by a deficiency of arylsulfatase A (ARSA). METHODS: We treated patients who had MLD with atidarsagene autotemcel (arsa-cel), a hematopoietic stem-cell-based gene therapy, in two prospective open-label clinical studies and expanded-access programs. We compared their outcomes with those of untreated patients (natural history cohort). The primary end point was survival free from severe motor impairment (the time from birth to the first occurrence of loss of locomotion and of sitting without support or death from any cause). RESULTS: A total of 39 treated patients and 49 untreated patients were included. The median follow-up was 6.76 years (range, 0.64 to 12.19). Arsa-cel resulted in a significantly lower risk of severe motor impairment or death than no treatment among patients with presymptomatic late-infantile MLD (P<0.001), those with presymptomatic early-juvenile MLD (P = 0.04), and those with early-symptomatic early-juvenile MLD (P<0.001). The estimated percentage of patients surviving without severe motor impairment at 6 years of age was 0% (95% confidence interval [CI], not evaluable) among untreated patients with late-infantile MLD and 100% (95% CI, 100 to 100) among treated patients with presymptomatic late-infantile MLD. The estimated percentage of patients surviving without severe motor impairment at 10 years of age was 11.2% (95% CI, 0.9 to 36.4) among untreated patients with early-juvenile MLD and 87.5% (95% CI, 38.7 to 98.1) and 80.0% (95% CI, 40.9 to 94.6) among treated patients with presymptomatic and early-symptomatic early-juvenile MLD, respectively. No evidence of insertional oncogenesis was found. The most common grade 3 or higher adverse event was febrile neutropenia. Anti-ARSA antibodies were detected transiently in 6 of 39 patients (15%). Three deaths occurred, all of which were considered by the investigators to be unrelated to arsa-cel. CONCLUSIONS: Among patients with presymptomatic late-infantile or early-juvenile MLD and those with early-symptomatic early-juvenile MLD, the risk of severe motor impairment or death was significantly lower among those who received treatment with arsa-cel than in a natural history cohort that did not receive treatment. (Funded by Orchard Therapeutics and others; ClinicalTrials.gov numbers, NCT01560182 and NCT03392987.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Fumagalli F, Calbi V, Gallo V, et al. Long-Term Effects of Atidarsagene Autotemcel for Metachromatic Leukodystrophy. N Engl J Med. 2025. PMID: 40267426. doi:10.1056/NEJMoa2405727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。